TARO PHARMACEUTICALS CANADA
Chirag Parekh possesses extensive experience in quality assurance and computer validation within the pharmaceutical industry. Currently serving as a Specialist in QA-IT & Computer Validation at Taro Pharmaceuticals Canada since February 2023, Chirag leads Global Computer Validation Activities across multiple sites and departments. Previous roles include Computerized System Validation Consultant at Apotex Inc., where responsibilities encompassed leading validation activities for various laboratory and manufacturing systems, as well as validation documentation. Additionally, work as a Validation Specialist at Compliance Associates involved enhancing products to meet industry requirements. Chirag has also contributed as a CSV Consultant at Celestica and held key positions at Zydus Group and Baxter International, focusing on computerized system validation, production supervision, and compliance with regulatory standards. Educational qualifications include a Master of Pharmacy in Medicinal and Pharmaceutical Chemistry from Gujarat Technological University and a Bachelor of Pharmacy from Veer Narmad South Gujarat University.
This person is not in any teams
TARO PHARMACEUTICALS CANADA
We are a global, research-driven, specialty pharmaceutical company. Established in 1950, Taro develops, manufactures and markets affordable prescription and over-the counter medications. With support from our parent company, Sun Pharma, the world's 5th largest specialty generic pharmaceutical company we are a powerful global presence. Our world class production facilities in Brampton, Ontario and nearly 600 Canadian employees give Taro Canada a uniquely Canadian perspective. Our Canadian focus on dermatology makes us a leading manufacturer and supplier of topical products such as creams, ointments, and gels. This investment in niche markets continues to differentiate Taro from our competitors. We specialize in generic prescription products, but also produce over the counter and brand name drugs. Our strong research program and niche strategy have positioned us as a central player in the specialty pharmaceutical sector.